InMed Pharmaceuticals Inc... (INM)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies.
The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa.
The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain.
In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases.
Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids.
It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics.
The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014.
InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Country | CA |
IPO Date | May 5, 2014 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 13 |
CEO | Eric A. Adams B.S. Chem., M.I.B. |
Contact Details
Address: 815 West Hastings Street Vancouver, BC CA | |
Website | https://www.inmedpharma.com |
Stock Details
Ticker Symbol | INM |
Exchange | NASDAQ |
Fiscal Year | July - June |
Reporting Currency | USD |
CIK Code | 0001728328 |
CUSIP Number | 457637601 |
ISIN Number | CA4576376012 |
Employer ID | 00-0000000 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Eric A. Adams B.S. Chem., M.I.B. | President, Chief Executive Officer & Director |
Michael Woudenberg P.Eng. | Chief Operating Officer |
N. Netta Jagpal | Chief Financial Officer & Corporate Secretary |
Alexandra Diane-Janet Mancini M.Sc. | Senior Vice President of Clinical & Regulatory Affairs |
Colin Clancy | Senior Director of Investor Relations |
Dr. Eric Chih-Hsien Hsu Ph.D. | Senior Vice President of Preclinical Research & Development |
Dr. Sazzad Hossain M.Sc., Ph.D. | Co-Founder |
Dr. Shane A. Johnson Ph.D. | Senior Vice President & GM of BayMedica |
Jerry P. Griffin | Vice President of Sales & Marketing |
Sarah Li CPA, CGA | Vice President of Accounting & Controller |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jan 22, 2025 | 8-K | Current Report |
Jan 21, 2025 | 8-K | Current Report |
Jan 03, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Jan 02, 2025 | 424B3 | Filing |
Dec 30, 2024 | S-1/A | [Amend] Filing |
Dec 23, 2024 | S-1 | Filing |
Dec 23, 2024 | 4 | Filing |
Dec 23, 2024 | 4 | Filing |
Dec 23, 2024 | 4 | Filing |
Dec 23, 2024 | 4 | Filing |